InspireMD, Inc. (NSPR) Dividend History

InspireMD, Inc. is a medical technology company specializing in the development of innovative devices for the treatment of cardiovascular diseases. The company is known for its proprietary MGuard technology, a embolic protection system designed to reduce the risk of heart attack during percutaneous coronary interventions. InspireMD focuses on providing solutions that improve patient outcomes and procedural safety in interventional cardiology.

4 Menorat Hamaor St., Tel Aviv, L3, 6744832
Phone: (888) 776-6804
Website: https://www.inspiremd.com

Dividend History

InspireMD, Inc. currently does not pay dividends

Company News

InspireMD Reports First Quarter 2025 Financial Results

InspireMD, a developer of the CGuard Prime carotid stent system, reported its Q1 2025 financial results. The company saw a 1.2% increase in revenue, but a significant increase in operating expenses, leading to a net loss of $11.2 million. The company remains optimistic about the upcoming FDA approval of its CGuard Prime system.

GlobeNewswire Inc.
InspireMD to Announce First Quarter 2025 Financial Results

InspireMD, Inc. (Nasdaq: NSPR) announced that it will release its Q1 2025 financial results on May 9, 2025, and host a conference call to discuss the results and recent highlights.

GlobeNewswire Inc.
InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

InspireMD and NAMSA are partnering to conduct a pivotal clinical trial for InspireMD's CGuard Prime™ 80 cm carotid stent system for use in Transcarotid Artery Revascularization (TCAR) procedures. The study aims to evaluate the safety and effectiveness of the TCAR procedure with the CGuard Prime stent.

GlobeNewswire Inc.
InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

InspireMD, a medical device company, announced the establishment of its global headquarters in Miami, Florida to support the anticipated U.S. launch and commercialization of its CGuard Prime carotid stent system in 2025, if approved by the FDA.

GlobeNewswire Inc.
InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

InspireMD has submitted a Premarket Approval (PMA) application to the FDA for its CGuard Prime carotid stent system, based on positive results from the C-GUARDIANS clinical trial. The company anticipates a U.S. commercial launch in H1 2025 if the device is approved.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 01:01:41 UTC